NEW YORK(GenomeWeb) – Agilent Technologies and Cartagenia said today that Agilent will acquire Cartagenia for an undisclosed sum.
The acquisition will provide Agilent with software solutions for its clinical genetics and molecular oncology customers, while providing stronger support and services for Cartagenia's clients, Jacob Thaysen, president of Agilent's Diagnostics and Genomics Group, said in a statement.
The acquisition is expected to be completed by May 19, subject to local laws and regulations and customary closing conditions, the companies said. As part of the deal, all 36 Cartagenia employees will be offered employment with Agilent, the firms said.
From its offices in Leuven, Belgium, and Boston, Cartagenia provides a suite of software solutions and services based on its Bench Lab platform for assessing, reporting, and sharing information on genomic variants from next-generation sequencing and microarray data in clinical contexts. The company's solutions are FDA-registered as exempt Class I Medical Devices in theUSand as Class I Medical Devices in Europe.
"Joining forces with Agilent is an excellent strategic fit and provides tremendous opportunity both for our customers ... and for our team," Herman Verrelst, Cartagenia's CEO, said in a statement.
He added that Cartagenia's customers will benefit from the integration of the firm's products with a broad family of solutions and a range of new applications.